Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash

Telix Pharmaceuticals (TLX) announced a $2.35 billion merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts. Telix, which is based in Melbourne, makes radiopharmaceuticals, a drug class that attaches radioactive isotopes to specific molecules. These can be trained to destroy cancer or provide medical imaging. ITM, or Isotope Technologies Munich, is the…